Tag
The APLMS launched a pilot Singapore–China–India Healthy Longevity Model, prioritizing real-world evidence, functional outcomes, and scalable prevention over biomarkers alone across a 2.8 billion-person region. No trial results were reported.
SHARP registry data reveal that biologic therapies improve clinical outcomes equally in severe asthma patients irrespective of smoking status, challenging prevailing prescribing hesitancy and advocating inclusive treatment approaches.
Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced ab
A significant proportion of real-world diabetic macular edema patients are excluded from clinical trials of anti-VEGF therapy due to stringent systemic criteria, disproportionately affecting racial minorities. This study highlights the need
This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti
This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.
This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl
A NIDDK workshop highlighted the crucial role of real-world evidence in addressing gaps about GLP-1 receptor agonists’ safety, effectiveness, adherence, and economic impact to improve clinical and regulatory decision-making.
A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation
This article reviews a large real-world study demonstrating cenobamate’s superior effectiveness over brivaracetam, lacosamide, and perampanel in reducing seizures for adults with drug-resistant focal epilepsy.
A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful
A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-en
A 3-year prospective study demonstrates sustained biochemical and clinical improvements with burosumab in XLH patients across pediatric and adult age groups, including those typically excluded from clinical trials.
This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.
A large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher inc
A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological out
A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha
